Cargando…

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans

Teneligliptin, a dipeptidyl peptidase-4 inhibitor, is used to treat type 2 diabetes mellitus. FMO3 and CYP3A4 metabolize teneligliptin into teneligliptin sulfoxide. This study examined the effects of FMO3 (rs909530, rs1800822, rs2266780, and rs2266782) and CYP3A4 (rs2242480) polymorphisms on tenelig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Jin-Woo, Kim, Kyoung-Ah, Kim, Jong-Min, Park, In-Hwan, Park, Ji-Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426351/ https://www.ncbi.nlm.nih.gov/pubmed/34512362 http://dx.doi.org/10.3389/fphar.2021.736317

Ejemplares similares

Rapid detection of FMO3 single nucleotide polymorphisms using a pyrosequencing method
por: Park, Jin-Woo, et al.
Publicado: (2022)

CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin
por: Park, Jin-Woo, et al.
Publicado: (2022)

ABCG2 Single Nucleotide Polymorphism Affects Imatinib Pharmacokinetics in Lower Alpha-1-Acid Glycoprotein Levels in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers
por: Tang, Yong-Jun, et al.
Publicado: (2017)

Effect of CYP3A4(∗)1G and CYP3A5(∗)3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects
por: Liu, Shuaibing, et al.
Publicado: (2017)

The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism
por: Gao, Nanyong, et al.
Publicado: (2022)

Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers
por: Nie, Shanshan, et al.
Publicado: (2022)

Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers
por: Jung, Eben, et al.
Publicado: (2018)

Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects
por: Chung, Hyewon, et al.
Publicado: (2023)

Borneol influences the pharmacokinetics of florfenicol through regulation of cytochrome P450 1A2 (CYP1A2), CYP2C11, CYP3A1, and multidrug resistance 1 (MDR1) mRNA expression levels in rats
por: LI, Xuting, et al.
Publicado: (2021)

The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice
por: Ceriello, Antonio, et al.
Publicado: (2019)

A compound heterozygous mutation in the FMO3 gene: the first pediatric case causes fish odor syndrome in Korea
por: Kim, Ji Hyun, et al.
Publicado: (2017)

Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes
por: Lee, Jin Sol, et al.
Publicado: (2013)

Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A
por: Rafehi, Muhammad, et al.
Publicado: (2019)

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
por: Calleja, Sofía, et al.
Publicado: (2023)

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
por: Grzegorzewski, Jan, et al.
Publicado: (2022)

CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients
por: Krall, Paola, et al.
Publicado: (2021)

Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
por: Contreras-Castillo, Stephania, et al.
Publicado: (2021)

Polymorphisms of the Flavin containing monooxygenase 3 (FMO3) gene do not predispose to essential hypertension in Caucasians
por: Dolan, Ciara, et al.
Publicado: (2005)

Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections
por: Chuwongwattana, Sumonrat, et al.
Publicado: (2020)

The Chinese herb Styrax triggers pharmacokinetic herb-drug interactions via inhibiting intestinal CYP3A
por: Zhang, Feng, et al.
Publicado: (2022)

Pharmacokinetics of marbofloxacin after intravenous and intramuscular administration in Hanwoo, Korean native cattle
por: BELEW, Sileshi, et al.
Publicado: (2014)

Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients
por: Lee, Fei Yee, et al.
Publicado: (2022)

Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients
por: Matthaei, Johannes, et al.
Publicado: (2021)

SAT-173 Antiproliferative Effect of Teneligliptin on Atherosclerosis in Vascular Smooth Muscle Cell
por: Moon, Shinje, et al.
Publicado: (2019)

Efficacy and safety of teneligliptin
por: Singh, Awadhesh Kumar
Publicado: (2017)

Effects of CYP3A4*22 polymorphism on trough concentration of tacrolimus in kidney transplantation: a systematic review and meta-analysis
por: Kim, Jung Sun, et al.
Publicado: (2023)

Production of drug metabolites by human FMO3 in Escherichia coli
por: Catucci, Gianluca, et al.
Publicado: (2020)

Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Li, Xiaoxuan, et al.
Publicado: (2018)

Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children
por: Cleary, Yumi, et al.
Publicado: (2023)

Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients
por: Chan, Sze Wa, et al.
Publicado: (2021)

Polymorphisms of CYP1A1 and GSTM1 Genes and Susceptibility to Oral Cancer
por: Cha, In-Ho, et al.
Publicado: (2007)

Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway
por: El-Serafi, Ibrahim, et al.
Publicado: (2017)

A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans
por: Ryu, S, et al.
Publicado: (2017)

Effect of CYP3A4 Inhibitors and Inducers on Pharmacokinetics and Pharmacodynamics of Saxagliptin and Active Metabolite M2 in Humans Using Physiological-Based Pharmacokinetic Combined DPP-4 Occupancy
por: Li, Gang, et al.
Publicado: (2021)

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction
por: Shi, Hong Ting, et al.
Publicado: (2021)

Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans
por: Park, Jin-Woo, et al.
Publicado: (2022)

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2020)

Natural Product Ginsenoside 20(S)-25-Methoxyl-Dammarane-3β, 12β, 20-Triol in Cancer Treatment: A Review of the Pharmacological Mechanisms and Pharmacokinetics
por: Kim, Dohyun, et al.
Publicado: (2020)

Influence of Genetic Admixture Components on CYP3A5*3 Allele-Associated Hypertension in Amerindian Populations From Northwest Mexico
por: Galaviz-Hernández, Carlos, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h4rs09jfjqhela4ocd3t60ng0t